The novelty of our research is that it’s the first hypothesis to recognize the critical importance of
the vein-lesion relationship in MS in designing an effective treatment for the disease. The significance of our research is that it is the first therapy that demonstrates improvement of disability in all phases of multiple sclerosis. No other therapies for MS have provided evidence that patients can recover ability as measured by standardized, quantitative mobility performance tests.